Showing results (11-20 of 16) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Pharmacogenetics and Genomics|February 25, 2011
Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis CAlexandra Doehring, Wolf Peter Hofmann, Christina Schlecker, et al.Journal of Clinical Psychopharmacology|January 26, 2023
Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I StudyMichael Desch, Christina Schlecker, Kathrin Hohl, et al.Clinical Drug Investigation|December 22, 2021
The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [14C]-BI 425809 in Healthy MalesUte Burkard, Michael Desch, Yury Shatillo, et al.Clinical and Translational Science|August 24, 2018
Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational StudiesHolger Rosenbrock, Michael Desch, Oliver Kleiner, et al.BMJ Open Respiratory Research|September 14, 2023
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)Toby M Maher, Shervin Assassi, Arata Azuma, et al.The New England Journal of Medicine|May 19, 2025
Nerandomilast in Patients with Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.Pageof 2